Off-Label Medication Use in Frontotemporal Dementia
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: There are no Food and Drug Administration (FDA)-approved medications indicated for the treatment of frontotemporal dementia (FTD). We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics. Methods: Medication and demographic data from the Alzheimer’s Disease Research Centers of California (ARCC) and a multicenter FTD natural history study (NHS) data set were compared in bvFTD and Alzheimer’s disease (AD), and effects of demographic variables were assessed using logistic regression. Results: Overall, the percentage of patients taking one or more FDA-approved AD or psychiatric medications was similar in bvFTD and AD; however, after controlling for demographic variables, acetylcholinesterase inhibitor (AChI) use was less common in bvFTD, whereas memantine use remained similar in the 2 groups. Conclusions: Despite lack of evidence for efficacy, the use of AChIs and memantine is common in bvFTD. Clinical trials should be pursued to determine the optimal therapeutic interventions for bvFTD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206
Development of methodology for conducting clinical trials in frontotemporal lobar degeneration
Knopman, D. S., Kramer, J. H., Boeve, B. F., Caselli, R. J., Graff-Radford, N. R., Mendez, M. F., Miller, B. L., & Mercaldo, N. (2008) · Brain · doi:10.1093/brain/awn234 · Cited by 442
Self-citationBehavioral disorders in the frontal and temporal variants of frontotemporal dementia
Liu, W., Miller, B. L., Kramer, J. H., Rankin, K., Wyss-Coray, C., Gearhart, R., Phengrasamy, L., Weiner, M., & Rosen, H. J. (2004) · Neurology · doi:10.1212/01.wnl.0000113729.77161.c9 · Cited by 313
Self-citationA systematic review of neurotransmitter deficits and treatments in frontotemporal dementia
Huey, E. D., Putnam, K. T., & Grafman, J. (2006) · Neurology · doi:10.1212/01.wnl.0000191304.55196.4d · Cited by 299
Preliminary Findings: Behavioral Worsening on Donepezil in Patients With Frontotemporal Dementia
Mendez, M. F., Shapira, J. S., McMurtray, A., & Licht, E. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000231744.69631.33 · Cited by 267 · cited 2×
“One open-label study suggested that rivastigmine was well tolerated in bvFTD,(9) and a recent placebo-controlled study demonstrated a potential benefit of galantamine in logopenic variants of primary progressive aphasia (who may have underlying AD pathology(10)); however, experience from a number of FTD-specialty clin…”
BackgroundResultSelf-citationGalantamine in Frontotemporal Dementia and Primary Progressive Aphasia
Kertesz, A., Morlog, D., Light, M., Blair, M., Davidson, W., Jesso, S., & Brashear, R. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000113034 · Cited by 217
Cited by
EFNS‐ENS Guidelines on the diagnosis and management of disorders associated with dementia
Sorbi, S., Hort, J., Erkinjuntti, T., Fladby, T., Gainotti, G., Gurvit, H., Nacmias, B., Pasquier, F., Popescu, B. O., Rektorova, I., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03784.x · Cited by 306
FTD and ALS: A Tale of Two Diseases
Ferrari, R., Kapogiannis, D., D. Huey, E., & Momeni, P. (2011) · Current Alzheimer Research · doi:10.2174/156720511795563700 · Cited by 272
Boxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., Mendez, M., Kerwin, D., Lerner, A., Wu, C.-K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70320-4 · Cited by 228
Self-citationFrontotemporal Lobar Degeneration: Epidemiology, Pathology, Diagnosis and Management
Seltman, R. E., & Matthews, B. R. (2012) · CNS Drugs · doi:10.2165/11640070-000000000-00000 · Cited by 132
Advances in treatment of frontotemporal dementia
Magrath Guimet, N., Zapata-Restrepo, L. M., & Miller, B. L. (2022) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.21060166 · Cited by 52
Self-citation
Metadata
- Authors
- Hu, B., Ross, L., Neuhaus, J., Knopman, D., Kramer, J., Boeve, B., Caselli, R. J., Graff-Radford, N., Mendez, M. F., Miller, B. L., & Boxer, A. L.
- Venue
- American Journal of Alzheimer's Disease & Other Dementias®
- Publisher
- SAGE Publications
- Published
- 2010-02-01
- Volume
- 25
- Issue
- 2
- Pages
- 128-133
- ISSN
- 0888-4897 (ISSN-L)
- 1533-3175
- 1938-2731
- OpenAlex
- W2029497354
- Cited by
- 56
- References
- 6
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Off-Label Medication Use in Frontotemporal Dementia. https://app.cochat.ai/papers/10.1177/1533317509356692
- The paper
- Hu, B., Ross, L., Neuhaus, J., Knopman, D., Kramer, J., Boeve, B., Caselli, R. J., Graff-Radford, N., Mendez, M. F., Miller, B. L., & Boxer, A. L. (2010). Off-Label Medication Use in Frontotemporal Dementia. American Journal of Alzheimer's Disease & Other Dementias®. https://doi.org/10.1177/1533317509356692
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.